Rating Change
Cantor Fitzgerald reiterated its Overweight rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) on November 13, 2026.
reiterateNASDAQ:ZVRA
Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA)
Cantor Fitzgerald reiterated its Overweight rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) on November 13, 2026.
At publication ·
What changed
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) · reiterate
- Firm
- Cantor Fitzgerald
- Rating
- Overweight to Overweight
- Price at event
- $9.08
- Market capitalization
- $472.3M
At a glance
Key takeaways
- Cantor Fitzgerald maintained an Overweight rating on Zevra Therapeutics (ZVRA) on November 13, 2026.
Market Context
Zevra Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $9.08 with a market capitalization of $472.3M. The stock has gained 18.4% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zevra Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Zevra Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 13, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Nov 13, 2026 | BTIG | Buy | N/A |
| Aug 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 07, 2026 | Guggenheim | Buy | N/A |
| Aug 06, 2026 | Citizens | Market Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ZVRA Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ZVRA?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Zevra Therapeutics, Inc. (NASDAQ:ZVRA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZVRA forecast page.